Published on
Updated
Reading 2 mins.
A new EPI-PHARE study has just been published by the Ansm-Cnam group. It focuses on the risk of myocarditis after vaccination with a messenger RNA vaccine. Result: the “risk of myocarditis is increased but remains low after the first booster dose” and “this risk decreases with the lengthening of the time between doses”.
EPI-PHARE evaluated the effect on the risk of myocarditis of the first booster dose (third dose) of an mRNA vaccine and the delay between the different doses.
A study conducted on all cases of myocarditis
This study was conducted on all cases of myocarditis occurring in patients aged at least 12 years, between December 27, 2020 and January 31, 2022, i.e. 4890 cases for 48,900 controls. “This study shows the existence of a risk of myocarditis after the first booster dose (third dose). This risk is lower than after the second dose and decreases with the lengthening of the time between successive doses. writes the National Agency for the Safety of Medicines and Health Products (ANSM) in its press release.
“The risk of myocarditis is increased during the first week following the administration of the third dose of the Comirnaty and Spikevax vaccines, but with a lower risk for the third dose compared to the second” adds the health authority.
Consult a GP online
One case of myocarditis for more than 300,000 vaccines
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane that surrounds the heart) can be caused by a viral infection such as Covid-19. They particularly affect young men.
“The excess of cases of myocarditis associated with the third dose is globally estimated at 0.25 cases per 100,000 doses of the Comirnaty vaccine and 0.29 cases per 100,000 doses of the Spikevax vaccine, corresponding to 1 case of myocarditis attributable to the vaccination. for the administration of 398,000 third doses of Comirnaty and 340,000 third doses of Spikevax” still indicates the ANSM.
“The largest excess cases were observed in men under 30, with a maximum of 1.2 cases per 100,000 third doses of Comirnaty, which corresponds to 1 case of myocarditis per 87,000 third doses..
Covid-19: the European Medicines Agency warns about the Novavax vaccine
The European Medicines Agency has just launched an alert concerning the anti-Covid vaccine from the American laboratory Novavax. Indeed, it could cause anaphylaxis.
“People who develop a strong allergic reaction after receiving the first dose of Nuvaxovid should not receive the second.” very clearly indicates the site of the European Medicines Agency, on its website. The vaccine, manufactured by the American laboratory novavax, was authorized in France in February 2022. It does not work on the principle of messenger RNA but it exposes the immune system to part of the virus, the Spike protein, to lead to the creation of antibodies
In Europe, approximately 216,000 doses were injected and 1,000 adverse effects reported. In France, 13,000 people have received this vaccine, mainly in Martinique, Guadeloupe, Guyana and Reunion.